METHODS FOR ASSESSING THE TREATMENT RESPONSE OF TNBC PATIENTS TO NEO-ADJUVANT CHEMOTHERAPY BY ANALYSING CPG METHYLATION

摘要

The present invention relates to methods for predicting the efficacy of anthracycline-based neo-adjuvant chemotherapy in triple-negative breast cancer. This is achieved by determining epigenetic changes within the PITX2 gene. Detection of the methylation state of Cp G sites in a genomic sequence of PITX2 allows an estimate of the response or failure of an individual breast cancer patient to neo-adjuvant therapy.